SJMB12 trial (vismodegib): what clinicians have said so far
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- NCT01878617 ↗
- Active, not recruiting
- St. Jude Children's Research Hospital
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on SJMB12 (vismodegib plus cyclophosphamide plus cisplatin plus vincristine; pemetrexed plus gemcitabine plus cyclophosphamide plus cisplatin; cyclophosphamide plus cisplatin plus vincristine in newly diagnosed medulloblastoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SJMB12 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Medulloblastoma
- Interventions
- Craniospinal Irradiation with boost to the primary tumor site; Cyclophosphamide; Cisplatin; Vincristine; Vismodegib; Pemetrexed; Gemcitabine; Aerobic Training; Neurocognitive Remediation
- Arms
- Stratum W1: Low Risk · Experimental
- Stratum W2: Atypical · Experimental
- Stratum W3: High Risk · Experimental
- Stratum S1: Standard Risk · Experimental
- Stratum S2: High Risk · Experimental
- Stratum N1: Standard Risk · Experimental
- Stratum N2: Intermediate Risk · Experimental
- Stratum N3: High Risk · Experimental
- Enrollment
- 660
- Primary outcomes
- Progression-free Survival in Stratum W1
- Progression-free Survival in Stratum N1
- Progression-free Survival in Stratum S1 Skeletally Mature Cohort
- Change in VO2 Peak Value
- Change in Spatial Span Backward Standard Score
- Sponsor
- St. Jude Children's Research Hospital with Genentech, Inc., National Cancer Institute (NCI)
- Start
- Jun 23, 2013
- Primary completion
- Oct 13, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT01878617 · updated Nov 13, 2025
Publications
linked from the registry- Gajjar A, Mahajan A, Bale T, Bowers DC, Canan L, Chi S, Cluster A, Cohen K, Cole B, Coven S, Darlington W, Dorris K, Elster J, Ermoian R, Franson A, George E, Helgager J, Landi D, Lin C, Metrock L, Nanda R, Palmer J, Partap S, Plant A, Pruthi S, Reynolds R, Stearns D, Storm P, Wang A, Wang LD, Whipple N, Zaky W, McMillian N, Ramakrishnan S. Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Mar;23(3):113-130. doi: 10.6004/jnccn.2025.0012. PubMed 40073837
- Khan RB, Patay Z, Klimo P, Huang J, Kumar R, Boop FA, Raches D, Conklin HM, Sharma R, Simmons A, Sadighi ZS, Onar-Thomas A, Gajjar A, Robinson GW. Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. Neuro Oncol. 2021 Sep 1;23(9):1586-1596. doi: 10.1093/neuonc/noab030. PubMed 33823018